Vascular Biogenics Ltd (VBLT)

[mantoo123]

August 14, 2017 company update from LifeSci Capital also intimates that VB-111 is efficient. The report states:

Iterestingly, the GLOBE study is an open-label trial, and so the quick enrollment may have been influenced by an efficacy signal with VB-111 observed by physicians.

However, Dr. Harats has repeatedly stated that his company is blinded and insists on being blinded.

I find these statements by Dr. Harats somewhat confusing as the clinical trials are open label.

WDYT?

staccani wrote:
If you read my previous posts you will understand what is going on. Many Signs pointing to a successful gbm ph3 result. Basically many know already how the trial is going; doctors and patients (as they are not blinded), DSMC, and i guess insiders as well ( they would just need to ask doctors or patients). The recent Lee family buy is another sign together with trial being now at avg 14 months treatment duration, the much quicker full Enrolment of gbm ph3 , company planning to open a mfg site to produce VB111 in large quantities and starting another ph3 both in q4. What else do we need to know (other than the official ph3 results)?